Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SSTR1 | P30872 | 1/20 | 0.57 |
| ▸ | SSTR2 | P30874 | 1/20 | 0.57 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.57 |
| ▸ | SSTR3 | P32745 | 1/20 | 0.57 |
| ▸ | SSTR5 | P35346 | 1/20 | 0.57 |
| ▸ | GJB2 | P29033 | 4/20 | 0.53 |
| ▸ | TACR2 | P21452 | 1/20 | 0.50 |
| ▸ | LGALS8 | O00214 | 1/20 | 0.50 |
| ▸ | NT5E | P21589 | 1/20 | 0.49 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.47 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.47 |
| ▸ | CDC25B | P30305 | 2/20 | 0.46 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.46 |
| ▸ | GJA1 | P17302 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13598718 | 1.00 | SSTR1 (0.57) | SSTR1SSTR2SSTR4SSTR3SSTR5 | |
| SCHEMBL18880005 | 1.00 | SSTR1 (0.57) | SSTR1SSTR2SSTR4SSTR3SSTR5 | |
| SCHEMBL11066790 | 1.00 | SSTR1 (0.57) | SSTR1SSTR2SSTR4SSTR3SSTR5 | |
| SCHEMBL17039948 | 1.00 | SSTR1 (0.57) | SSTR1SSTR2SSTR4SSTR3SSTR5 | |
| SCHEMBL18671860 | 1.00 | SSTR1 (0.57) | SSTR1SSTR2SSTR4SSTR3SSTR5 | |
| SCHEMBL5981855 | 1.00 | SSTR1 (0.57) | SSTR1SSTR2SSTR4SSTR3SSTR5 | |
| SCHEMBL24371601 | 1.00 | SSTR1 (0.57) | SSTR1SSTR2SSTR4SSTR3SSTR5 | |
| SCHEMBL12896366 | 1.00 | SSTR1 (0.57) | SSTR1SSTR2SSTR4SSTR3SSTR5 | |
| SCHEMBL1262725 | 1.00 | SSTR1 (0.57) | SSTR1SSTR2SSTR4SSTR3SSTR5 | |
| SCHEMBL31491491 | 1.00 | SSTR1 (0.57) | SSTR1SSTR2SSTR4SSTR3SSTR5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-120118141-A | Nucleoside analogues and uses thereof | 广州市恒诺康医药科技有限公司 | 2025-06-10 | — | — | CN | disclosed |
| CN-119930717-A | 1-Triazole ribose derivative and preparation method and application thereof | 上海泓博智源医药股份有限公司 | 2025-05-06 | — | — | CN | disclosed |
| US-20140066398-A1 | HCV POLYMERASE INHIBITORS | MEDIVIR, AB (SE) | 2014-03-06 | — | — | US | disclosed |
| WO-2013084165-A1 | HCV POLYMERASE INHIBITORS | MEDIVIR AB (SE) | 2013-06-13 | — | — | WO | disclosed |
| US-20130143835-A1 | HCV Polymerase Inhibitors | MEDIVIR AB (SE) | 2013-06-06 | — | — | US | disclosed |
| US-8133870-B2 | Therapeutic furopyrimidines and thienopyrimidines | BIOCRYST PHARMACEUTICALS, INC. (US) | 2012-03-13 | — | — | US | disclosed |
| US-20080300200-A1 | Therapeutic Furopyrimidines and Thienopyrimidines | BIOCRYST PHARMACEUTICALS, INC. (US) | 2008-12-04 | — | — | US | disclosed |
| US-7429571-B2 | Therapeutic furopyrimidines and thienopyrimidines | BIOCRYST PHARMACEUTICALS, INC. (US) | 2008-09-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080300200-A1 | Therapeutic Furopyrimidines and Thienopyrimidines | DPYD, TYMP, TYMS | SSTR1 4452/4885SSTR2 4263/4885SSTR4 4099/4885 |
| US-20130143835-A1 | HCV Polymerase Inhibitors | POLI, HAVCR2, EIF2AK2 | SSTR1 4414/4885SSTR2 4197/4885SSTR4 4286/4885 |
| US-20140066398-A1 | HCV POLYMERASE INHIBITORS | POLI, HAVCR2, EIF2AK2 | SSTR1 4414/4885SSTR2 4197/4885SSTR4 4286/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.